CMS Targets SubQ Keytruda and Opdivo Loophole; Takeda Beats Sotyktu Head-to-Head

BridgeBio's rare muscle disorder drug BBP-418 sweeps every endpoint in its Phase 3, the stock jumps fifteen percent, and a disease with zero approved treatments may finally have one on the way.

Meanwhile, FDA staff are already poking holes in Moderna's flu vaccine data two days before the AdCom vote, and Neumora just abandoned its lead depression drug after back-to-back Phase 3 failures.

Welcome to The Pharma Closeout for Tuesday, June sixteenth, twenty twenty-six. I'm Alex Mercer.

And I'm Maya Patel. Let's get into it.

Top story. BridgeBio reported today that BBP-418 met all primary and secondary endpoints in a Phase 3 trial for limb-girdle muscular dystrophy. The biomarker headline: glycosylated alpha-dystroglycan increased one-point-eight-fold from baseline at three months versus essentially no change on placebo. The trial also showed improvements in both motor function and lung function. Shares up about fifteen percent on the news. Reuters called this a best-case outcome.

One-point-eight-fold glycosylation rescue at three months is a clean magnitude — and what matters is that motor and lung function both moved in the same timeframe. In a progressive myopathy, functional endpoints tracking alongside the biomarker rather than lagging behind it tells you the downstream tissue-level response is real, not biochemical noise.

And there are no approved treatments for this condition. If BBP-418 holds through a filing, BridgeBio owns a first-in-disease commercial opportunity with zero on-market competition.

If the durability holds, yes — but the FDA is going to stress the chronic disease question. Three months of functional improvement is necessary but not sufficient for a lifelong progressive condition. BridgeBio needs to show that glycosylation rescue is sustained, not a peak-and-plateau. The agency has shown flexibility on dataset duration in rare disease, but only when the effect magnitude is unambiguous.

This also extends BridgeBio's broader build. They've got acoramidis generating revenue in transthyretin amyloidosis — BBP-418 now gives them a second potential rare disease franchise.

The sharper way to read that is where the execution risk shifts. The science is encouraging. But building specialty neuromuscular commercial infrastructure while running an existing ATTR-CM operation requires a different kind of organizational muscle — and patient-finding in limb-girdle muscular dystrophy alone will test whether they've built it.

Different approach to franchise-building from Lilly today. They announced they're acquiring Austin-based 4E Therapeutics, a company developing oral MNK inhibitors for chronic pain. The lead compound, 4ET1103, targets the MNK pathway in peripheral sensory neurons — a non-opioid approach designed to block pain signaling without central nervous system effects. Terms were not disclosed.

This is where I want to spend the mechanism budget. MNK inhibition for pain is genuinely novel — the pathway controls translational regulation in nociceptive neurons. 4E's thesis is that you can interrupt the molecular switch that converts acute pain into chronic pain without ever crossing the blood-brain barrier. That peripheral selectivity is the whole bet. The chronic pain efficacy graveyard runs deep, though — Lilly is wagering their translational engine can push this target through where others have stalled.

And Lilly was busy beyond pain. They also reported early positive data for a JAK inhibitor picked up through their Ajax acquisition, showing encouraging effects in patients with myelofibrosis — potentially setting up a long-term challenge to Incyte's Jakafi.

An early-stage myelofibrosis asset isn't going to move Jakafi share anytime soon. But it signals Lilly is quietly building optionality in hematology — a space most people associate with their oncology competitors, not Indianapolis.

Elsewhere, Adaptive Biotechnologies announced plans to split its MRD diagnostics business from its Immune Medicine drug discovery arm. The MRD unit grew revenue from a hundred and three million in twenty twenty-three to two hundred and twelve million in twenty twenty-five, and it's already profitable. Separation structure to be finalized by year-end.

On the pipeline side, Edgewise reported positive twelve-week Phase 2 data from the CIRRUS-HCM trial — their cardiac drug EDG-7500 showed NT-proBNP response rates above seventy-four percent across both obstructive and nonobstructive hypertrophic cardiomyopathy. Phase 3 planned for Q4.

That's the number to underline. Most cardiac myosin inhibitors have concentrated their evidence in the obstructive population. Seventy-four percent NT-proBNP response spanning both subtypes, if it holds at pivotal scale, would carve out clearly differentiated positioning where the nonobstructive cohort has been chronically underserved.

Quick hits on the negative side of the ledger. Neumora is discontinuing navacaprant after KOASTAL-2 and KOASTAL-3 both missed primary and key secondary endpoints in major depressive disorder — the company is implementing a major workforce reduction. Be Biopharma terminated its hemophilia B cell therapy trial. And enGene is implementing a substantial workforce reduction. to preserve cash ahead of a potential BLA filing for its bladder cancer gene therapy.

Flip the page, though — the IPO window keeps widening. Parabilis set a record with a six-hundred-and-seventy-million-dollar biotech offering — per BioPharma Dive, the largest ever for a venture-backed biotech. That extends a twenty-twenty-six streak where twelve drug startups have now raised over four-point-one billion combined.

The dual dynamic right now — big pharma acquiring aggressively while the IPO window reopens — means the strongest Phase 2 assets have more exit optionality than they've had in years. For a company like Edgewise heading into a pivotal trial, that environment could accelerate a partnership conversation well before data drops.

On the regulatory front, the story everyone should be reading tonight is the FDA briefing documents for Moderna's mFlusiva. They dropped today ahead of Thursday's VRBPAC meeting. The headline: reviewers found no major deficiencies, and mFlusiva met all pre-specified success criteria — noninferiority, superiority, and super-superiority — relative to a standard-dose flu vaccine.

That reads like a clean runway. Where's the tension?

Three places. First, the trial captured only a single flu season, so performance against different circulating strains is an open question. Second, sample size wasn't powered to demonstrate clear efficacy against influenza B. And third — this is where Thursday's debate will center — the comparator arm used a standard-dose vaccine, but for the sixty-five-and-older population, clinical practice already favors high-dose, adjuvanted, or recombinant shots. The FDA is essentially asking the panel: did Moderna beat the right baseline? In a population where the comparator doesn't reflect actual prescribing, that relative efficacy advantage becomes much harder to interpret.

And remember, this is the vaccine the FDA controversially refused to review earlier this year before reversing course.

Which is exactly what makes Thursday an inflection point beyond this one product. Moderna's entire post-COVID diversification narrative runs through the flu franchise. They installed Novartis veteran Ester Banque as Chief Commercial Officer effective yesterday and expanded President Stephen Hoge's role across R&D, manufacturing, and commercial — all explicitly to prepare for multiple launches in twenty twenty-seven and twenty twenty-eight. A negative AdCom vote doesn't just delay mFlusiva. It undercuts the organizational build-out Moderna is already staffing for.

Also worth noting on the regulatory side — Colorado became the second state after Florida to receive FDA approval to import prescription drugs from Canada. The state estimates significant savings on imported medications. And separately, Traws Pharma saw a significant decline Monday. after deferring its Phase 2a flu study of tivoxavir marboxil following a negative MHRA review.

Colorado is the one with structural legs. Pharma has fought state-level importation for years — a second state clearing the FDA pathway creates the kind of precedent other governors will cite in their own applications. The pricing pressure won't show up in earnings this quarter, but the political momentum behind importation just got meaningfully harder to unwind.

Looking ahead — Thursday's VRBPAC vote on mFlusiva is the week's single biggest catalyst. The panel votes on two separate questions: risk-benefit in adults fifty to sixty-four, and separately in the sixty-five-and-older group. Given the comparator controversy, that second vote is the one that could split the room.

Beyond Thursday, track Edgewise's Phase 3 setup through Q4 and BridgeBio's path toward a BBP-418 filing. Both stories got materially more interesting today — and both could look very different by fall.

That's your Pharma Closeout for Tuesday. BridgeBio delivering a clean Phase 3 sweep in limb-girdle muscular dystrophy, Lilly buying its way into non-opioid pain with 4E, Edgewise earning a Phase 3 ticket in HCM, and Moderna heading into a high-stakes AdCom Thursday with the FDA already showing its cards. If this briefing keeps you sharp, follow us on Spotify and drop a rating — it helps other pharma professionals find the show.

Lot of threads to pull on this week. Take care of yourselves, and we'll see you tomorrow.